Patients with CSCC who had lymphovascular invasion had a greater incidence of metastasis and disease-specific death than those without.

Eligible patients with previously untreated, metastatic squamous non–small-cell lung cancer (NSCLC) were randomly assigned 1:1 to pembrolizumab 200 mg or placebo plus carboplatin and ...